Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Controlled, Randomized, Double-blind Clinical Trial, 24 Months Duration, to Compare the Efficacy, Safety and Tolerability of Andrographolide Versus Placebo in Patients With Progressive Forms of Multiple Sclerosis

NCT02273635 is registered in ClinicalTrials.gov with Innobioscience SpA as lead sponsor.

NCT NCT02273635
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02273635 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Controlled, Randomized, Double-blind Clinical Trial, 24 Months Duration, to Compare the Efficacy, Safety and Tolerability of Andrographolide Versus Placebo in Patients With Progressive Forms of Multiple Sclerosis
Lead sponsor
Innobioscience SpA
Phase
Phase 1/2
Overall status
Unknown status
Start date
September 30, 2014
Completion date
April 30, 2017
Enrollment
68 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

multiple sclerosis, secondary progressive, primary progressive multiple sclerosis